230 related articles for article (PubMed ID: 32568176)
1. miR-638 in circulating leukaemia cells as a non-invasive biomarker in diagnosis, treatment response and MRD surveillance of acute promyelocytic leukaemia.
Bai Y; Chen C; Guo X; Ding T; Yang X; Yu J; Yang J; Ruan J; Zheng X; Chen Z
Cancer Biomark; 2020; 29(1):125-137. PubMed ID: 32568176
[TBL] [Abstract][Full Text] [Related]
2. Circulating lnc-LOC as a novel noninvasive biomarker in the treatment surveillance of acute promyelocytic leukaemia.
Wang G; Yan G; Sang K; Yang H; Sun N; Bai Y; Xu F; Zheng X; Chen Z
BMC Cancer; 2022 May; 22(1):481. PubMed ID: 35501730
[TBL] [Abstract][Full Text] [Related]
3. Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia.
Rusiniak ME; Yu M; Ross DT; Tolhurst EC; Slack JL
Cancer Res; 2000 Apr; 60(7):1824-9. PubMed ID: 10766166
[TBL] [Abstract][Full Text] [Related]
4. Transcription therapy for acute promyelocytic leukaemia.
Douer D
Expert Opin Investig Drugs; 2000 Feb; 9(2):329-46. PubMed ID: 11060680
[TBL] [Abstract][Full Text] [Related]
5. Expression of human Krüppel-like factor 3 in peripheral blood as a promising biomarker for acute leukemia.
Yan M; Liu H; Xu J; Cen X; Wang Q; Xu W; Wang W; Qiu Z; Ou J; Dong Y; Zhu P; Ren H; He F; Wang M
Cancer Med; 2020 Apr; 9(8):2803-2811. PubMed ID: 32101374
[TBL] [Abstract][Full Text] [Related]
6. Retinoic Acid-Induced Gene G(RIG-G) as a Novel Monitoring Biomarker in Leukemia and Its Clinical Applications.
Wang F; Tian J; Pang L; Wu J; Shang A; Sun Z; Li D; Yan J; Quan W
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356051
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNA HOTAIR regulates myeloid differentiation through the upregulation of p21 via miR-17-5p in acute myeloid leukaemia.
Hu L; Liu J; Meng Y; Zheng H; Ding C; Wang H; Charwudzi A; Li M; Li J; Zhai Z; Xiong S
RNA Biol; 2021 Oct; 18(10):1434-1444. PubMed ID: 33241756
[TBL] [Abstract][Full Text] [Related]
8. [microRNAs expression profile in acute promyelocytic leukemia cell differentiation induced by all-trans retinoic acid and arsenic trioxide].
Wu Y; Li XF; Yang JH; Liao XY; Chen YZ
Zhonghua Xue Ye Xue Za Zhi; 2012 Jul; 33(7):546-51. PubMed ID: 22967415
[TBL] [Abstract][Full Text] [Related]
9. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
10. Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia.
Fayyad-Kazan H; Bitar N; Najar M; Lewalle P; Fayyad-Kazan M; Badran R; Hamade E; Daher A; Hussein N; ElDirani R; Berri F; Vanhamme L; Burny A; Martiat P; Rouas R; Badran B
J Transl Med; 2013 Feb; 11():31. PubMed ID: 23391324
[TBL] [Abstract][Full Text] [Related]
11. PML-RARα interferes with erythropoiesis by repressing LMO2 in acute promyelocytic leukaemia.
Yang X; Tan Y; Wang P; Zhang H; Zhao M; Zhao X; Wang K
J Cell Mol Med; 2018 Dec; 22(12):6275-6284. PubMed ID: 30320491
[TBL] [Abstract][Full Text] [Related]
12. Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia.
Juul-Dam KL; Ommen HB; Nyvold CG; Walter C; Vålerhaugen H; Kairisto V; Abrahamsson J; Alm SJ; Jahnukainen K; Lausen B; Reinhardt D; Zeller B; von Neuhoff N; Fogelstrand L; Hasle H
Br J Haematol; 2020 Jul; 190(2):198-208. PubMed ID: 32175599
[TBL] [Abstract][Full Text] [Related]
13. Pulsed ATRA as single therapy restores long-term remission in PML-RARalpha-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study.
Visani G; Buonamici S; Malagola M; Isidori A; Piccaluga PP; Martinelli G; Ottaviani E; Grafone T; Baccarani M; Tura S
Leukemia; 2001 Nov; 15(11):1696-700. PubMed ID: 11681409
[TBL] [Abstract][Full Text] [Related]
14. Low expression of microRNA-340 confers adverse clinical outcome in patients with acute myeloid leukemia.
Wang Q; Feng T; Xu J; Miao MH; Ji XQ; Zhu H; Shao XJ
J Cell Physiol; 2019 Apr; 234(4):4200-4205. PubMed ID: 30171606
[TBL] [Abstract][Full Text] [Related]
15. Acute promyelocytic leukemia derived extracellular vesicles conserve PML-RARα transcript from storage-inflicted degradation: a stable diagnosis tool in APL patients.
Barzegar M; Farsani MA; Rafiee M; Amiri V; Parkhihdeh S; Rad F; Mohammadi MH
Ann Hematol; 2021 Sep; 100(9):2241-2252. PubMed ID: 34236496
[TBL] [Abstract][Full Text] [Related]
16. Vav1 is necessary for PU.1 mediated upmodulation of miR-29b in acute myeloid leukaemia-derived cells.
Vezzali F; Grassilli S; Lambertini E; Brugnoli F; Patergnani S; Nika E; Piva R; Pinton P; Capitani S; Bertagnolo V
J Cell Mol Med; 2018 Jun; 22(6):3149-3158. PubMed ID: 29532991
[TBL] [Abstract][Full Text] [Related]
17. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
18. PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.
Bräuer-Hartmann D; Hartmann JU; Wurm AA; Gerloff D; Katzerke C; Verga Falzacappa MV; Pelicci PG; Müller-Tidow C; Tenen DG; Niederwieser D; Behre G
Cancer Res; 2015 Aug; 75(16):3411-24. PubMed ID: 26041820
[TBL] [Abstract][Full Text] [Related]
19. The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease.
Mistry AR; Pedersen EW; Solomon E; Grimwade D
Blood Rev; 2003 Jun; 17(2):71-97. PubMed ID: 12642121
[TBL] [Abstract][Full Text] [Related]
20. A network including PU.1, Vav1 and miR-142-3p sustains ATRA-induced differentiation of acute promyelocytic leukemia cells - a short report.
Grassilli S; Nika E; Lambertini E; Brugnoli F; Piva R; Capitani S; Bertagnolo V
Cell Oncol (Dordr); 2016 Oct; 39(5):483-489. PubMed ID: 27480083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
